BOSTON SCIENTIFIC $BSX Q3’26 EARNINGS HIGHLIGHTS 🔹 Net Sales: $5.1B (Est. $5.05B) 🟢 🔹 Adj. EPS: $0.73 (Est. $0.72) 🟢; -3% YoY 🔹 GAAP EPS: $0.40; -22% YoY FY26 Guide: 🔹 Adj. EPS: $3.16-$3.18 (Est. $3.23) 🔴 🔹 Reported Net Sales Growth: ~+4.25% 🔹 Organic Net Sales Growth: ~+3.75% Q4 Guide: 🔹 Adj. EPS: $0.77-$0.79 (Est. $0.84) 🔴 🔹 Reported Net Sales Growth: -3.0% to -1.0% 🔹 Organic Net Sales Growth: -3.0% to -1.0% Segment Net Revenue: 🔹 MedSurg: $1.7B; +0.6% YoY 🔹 Cardiovascular: $3.4B; +1.9% YoY 🔹 Endoscopy: $741M; -0.8% YoY 🔹 Urology: $661M; -3.2% YoY 🔹 Neuromodulation: $331M; +13.1% YoY Announcements: 🔹 StoneSmart Solutions: FDA 510(k) clearance for two technologies 🔹 SEISMIQ: FDA 510(k) clearance for expanded sizing 🔹 Renal Denervation: Category I CPT codes effective January 2028 Other Q3 Metrics: 🔹 Net Sales Growth: +1.5% reported; +1.5% organic Comments: 🔸 “particularly to the cybersecurity incident, working with urgency and resilience to restore operations and continue supporting customers and patients.” 🔸 “As we move forward, I remain confident in our long-term strategy, fueled by our dedicated talent, differentiated portfolio and strong pipeline of meaningful innovation.”